The global Clinical Oncology NGS Market size was estimated at USD 8206 million in 2025 and is expected to reach USD 20914 million by 2032, growing at a CAGR of 14.3% from 2025 to 2032. Growth is primarily driven by the expanding clinical use of comprehensive genomic profiling and therapy-selection workflows that increasingly require NGS-based tumor profiling, companion diagnostics, and longitudinal monitoring across solid tumors and hematologic malignancies. Demand is further supported by faster clinical translation of biomarker discovery into test menus and by scaling adoption across high-volume hospital systems and reference laboratories in major regions.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2025
Forecast Period
2026-2032
Clinical Oncology Next Generation Sequencing (NGS) Market Size 2025
USD 8206 million
Clinical Oncology Next Generation Sequencing (NGS) Market, CAGR
14.3%
Clinical Oncology Next Generation Sequencing (NGS) Market Size 2032
USD 20914 million
Key Market Trends & Insights
The market is projected to expand at a CAGR of 14.3% during 2025–2032, indicating sustained multi-year growth in clinical oncology sequencing adoption.
North America accounted for 43.60% of global revenue in 2025, supported by higher penetration of precision oncology pathways and testing infrastructure.
Kits, Reagents, and Consumables held 56.80% share in 2025, reflecting recurring per-test usage intensity and standardized clinical workflows.
Targeted Sequencing / Targeted Resequencing led with 47.60% share in 2025, benefiting from clinical actionability and streamlined interpretation versus broader approaches.
Asia Pacific is expected to register the fastest growth over the forecast period, driven by rapid expansion of sequencing capacity, increasing oncology diagnostics volumes, and wider adoption of precision oncology testing across hospital systems and reference laboratories.
Segment Analysis
Clinical oncology NGS demand is increasingly shaped by routine adoption of comprehensive genomic profiling across diagnosis, therapy selection, and ongoing disease management. Providers prioritize workflows that deliver clinically interpretable results with reliable turnaround times, which strengthens adoption of validated targeted panels and standardized reporting approaches. As test volumes rise, operational considerations such as batching efficiency, sample-to-report traceability, and quality control requirements become central to purchasing decisions across care settings.
Liquid biopsy and monitoring use-cases are broadening the testing footprint beyond a single tissue-based event. Longitudinal pathways such as relapse surveillance and response tracking expand repeat testing potential and increase reliance on robust informatics pipelines for variant interpretation and reporting consistency. These dynamics reinforce demand for integrated ecosystems spanning sample preparation, sequencing, analytics, and clinical integration.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Kits, Reagents, and Consumables accounted for the largest share of 56.8% in 2025. The category leads because every clinical test run requires repeat purchasing of preparation and sequencing consumables, creating a structurally recurring revenue profile. Labs also standardize around validated reagent sets to maintain consistency across runs and reduce repeat testing caused by QC failures. Expanding assay menus for tumor profiling and liquid biopsy further increase replenishment frequency across high-throughput settings.
By Technology Insights
Targeted Sequencing / Targeted Resequencing accounted for the largest share of 47.6% in 2025. Targeted approaches remain preferred in clinical settings because they align tightly with actionable biomarkers and established clinical guidelines. They also reduce data complexity and interpretation burden, helping labs deliver consistent, reportable findings within practical turnaround windows. Growing use of panel-based profiling in treatment selection continues to reinforce targeted sequencing leadership.
By Workflow Insights
Sequencing accounted for the largest share of 39.0% in 2025. Sequencing remains the core throughput step that determines run capacity, turnaround time, and per-sample economics for clinical laboratories. Platform performance, run stability, and workflow automation strongly influence adoption decisions in high-volume oncology testing environments. As clinical volume expands, sequencing efficiency and reproducibility remain primary drivers sustaining this workflow’s leadership.
By Application Insights
Companion Diagnostics accounted for the largest share of 34.2% in 2025. Companion diagnostics lead due to therapy labeling and biomarker-driven treatment decisions that require validated testing to guide prescribing and eligibility. NGS-based panels increasingly consolidate multiple biomarkers into a single test, supporting CDx utilization across tumor types. Continued expansion of targeted therapies and biomarker-linked clinical pathways sustains demand for CDx-focused sequencing.
By End User Insights
Hospitals accounted for the largest share of 38.1% in 2025. Hospitals lead because cancer centers increasingly embed genomic testing into multidisciplinary care pathways, supporting in-house ordering and integrated clinical decision-making. Larger hospital systems also benefit from consolidated procurement, standardized protocols, and direct alignment with oncology service lines. As precision oncology expands, hospitals remain a central hub for initiating testing and coordinating downstream therapy choices.
Clinical Oncology Next Generation Sequencing (NGS) Market Drivers
Expansion of precision oncology and biomarker-led treatment decisions
Precision oncology is expanding across tumor types as clinicians increasingly rely on genomic biomarkers to select therapies and stratify patients. Clinical oncology sequencing enables multi-gene assessment in a single workflow, improving efficiency versus sequential single-marker testing. Broader availability of targeted therapies and biomarker-based guidelines encourages higher test volumes. Hospital systems and reference labs are scaling capacity to meet demand for clinically interpretable genomic reports.
For instance, Foundation Medicine’s FoundationOne CDx examines 324 genes in a single tissue assay, and its analytical validation was reported across more than 30,000 test results, supporting its use in high-volume precision oncology workflows.
Rising use of comprehensive genomic profiling in routine care
Comprehensive profiling is becoming more embedded in routine oncology decision-making to capture actionable alterations and guide personalized pathways. This elevates demand for standardized panels and validated workflows that produce consistent, reportable results. As testing becomes more routine, labs prioritize platforms and consumables that support reliability at scale. The shift toward consolidated panel testing also supports broader adoption across care settings.
For instance, Illumina’s TruSight Oncology 500 targets 523 genes, evaluates both tumor mutational burden and microsatellite instability in the same assay, and in an analysis of 1,102 lung, melanoma, and colorectal cancer samples showed R2=0.84 concordance with whole-exome sequencing for tumors below 30 mutations per megabase.
Growth of liquid biopsy and longitudinal monitoring pathways
Liquid biopsy expands access where tissue is limited and supports repeat testing over time, which can increase overall sequencing utilization. Monitoring applications such as response tracking and relapse surveillance intensify the need for robust assay performance and repeatable workflows. These use-cases also raise the importance of high-quality interpretation and reporting to ensure clinical actionability. As longitudinal pathways mature, testing volumes can extend beyond initial diagnosis.
Scaling of clinical lab infrastructure and integrated bioinformatics
Clinical labs are investing in operational throughput, automation, and analytics to manage larger testing volumes with consistent turnaround times. This strengthens demand for integrated ecosystems that connect sequencing output to interpretation and reporting workflows. Improved pipelines reduce manual interpretation burden and enable broader adoption beyond top-tier centers. As clinical sequencing scales, informatics becomes a key enabler of wider, standardized deployment.
Clinical Oncology Next Generation Sequencing (NGS) Market Challenges
Clinical oncology sequencing faces constraints related to data interpretation complexity, standardization, and clinical reporting requirements. Variants of uncertain significance and tumor heterogeneity can complicate reporting and limit consistent actionability across settings. Laboratories must maintain strict quality management systems, validation protocols, and compliance workflows, which adds cost and operational burden. These factors can slow adoption for smaller labs and constrain expansion beyond established centers.
For instance, Roche’s FoundationOne Liquid CDx uses targeted hybrid-capture sequencing to analyze 324 genes, is FDA-approved to report short variants in 311 genes, and its approval was supported by validation studies covering more than 7,500 samples and 30,000 unique variants across more than 30 cancer types, highlighting the scale of evidence and reporting rigor required for broad-panel clinical oncology testing.
Another challenge is the uneven depth of reimbursement, infrastructure, and specialist availability across regions and care settings. High upfront investment for platforms, skilled personnel, and informatics can deter broader rollout in resource-constrained markets. Differences in clinical guidelines, payer policies, and local regulatory expectations can further fragment adoption patterns. As a result, suppliers must balance clinical-grade robustness with cost-efficient scalability.
Clinical Oncology Next Generation Sequencing (NGS) Market Trends and Opportunities
An important trend is the growing emphasis on streamlined clinical workflows that reduce sample-to-report complexity and improve operational consistency. Providers increasingly favor integrated solutions that combine validated assays, automation, and standardized interpretation to support predictable turnaround times. This creates opportunities for end-to-end ecosystems that lower adoption friction and support scaled deployment across multi-site lab networks. As adoption expands, differentiation shifts toward reproducibility, clinical evidence, and workflow efficiency.
Another major opportunity lies in expanding monitoring-oriented use-cases and broader adoption of liquid biopsy-informed pathways. As MRD monitoring and longitudinal surveillance gain traction, repeat testing can rise and strengthen consumables intensity. This also increases the importance of data analysis and interpretation capabilities, opening opportunities for advanced analytics, standardized reporting, and integration with clinical systems. Suppliers that align with emerging monitoring pathways can capture sustained demand growth.
For instance, Guardant Health’s tissue-free Guardant Reveal test, evaluated across 1,900+ longitudinal samples from 342 patients in the COSMOS study, achieved 91% sensitivity at allele frequencies as low as 0.01%, delivered results within 7 days, and detected recurrence 3–8 months ahead of imaging with 90% of MRD-negative patients remaining relapse-free post-surgery.
Regional Insights
North America
North America held 43.60% share in 2025, supported by strong precision oncology penetration, higher test utilization, and mature clinical lab infrastructure. The region benefits from advanced cancer center networks and broader availability of validated oncology assays. Demand is reinforced by routine integration of genomics into therapy selection and by the scaling of high-throughput reference laboratory models. Platform ecosystems and informatics integration remain key adoption drivers across the region.
Europe
Europe accounted for 25.70% share in 2025, reflecting steady adoption across major oncology markets with expanding genomic medicine programs. National sequencing initiatives and tertiary cancer centers continue to increase routine use of tumor profiling and companion diagnostics. Labs emphasize standardized workflows, strong quality frameworks, and reproducible reporting aligned with clinical pathways. Ongoing capacity expansion and cross-border evidence development continue to support growth.
Asia Pacific
Asia Pacific represented 23.40% share in 2025 as sequencing capacity scales across large patient bases. Adoption is strengthened by rising oncology diagnostics volume, expanding lab networks, and increasing use of precision approaches in large urban centers. The region also shows accelerating interest in liquid biopsy and monitoring applications as access improves. Growth opportunities are supported by infrastructure build-out and wider diffusion of clinical genomics expertise.
Latin America
Latin America contributed 4.20% share in 2025, with adoption concentrated in larger economies and private reference laboratory ecosystems. Growth is supported by gradual expansion of oncology diagnostics access and by increasing clinician awareness of biomarker-led pathways. Capacity and reimbursement variability remain key constraints, keeping overall penetration lower than in more mature regions. Suppliers that enable scalable, cost-efficient workflows can expand reach across the region.
Middle East & Africa
Middle East & Africa held 3.10% share in 2025, with adoption centered on higher-resource markets and select advanced oncology centers. Growth is driven by gradual expansion of diagnostic infrastructure and targeted investments in specialized testing capabilities. The region remains heterogeneous, and adoption varies with reimbursement depth, lab capacity, and specialist availability. Scalable service models and partnerships can help broaden access over time.
Competitive Landscape
The competitive landscape is shaped by platform ecosystems spanning sequencing instruments, recurring consumables, clinical-grade assay menus, and interpretation software that supports standardized reporting. Suppliers compete on assay performance, workflow reliability, turnaround time, and evidence generation aligned to clinical oncology pathways. Differentiation also reflects the ability to support multiple use-cases such as companion diagnostics, tumor profiling, liquid biopsy, and monitoring with scalable lab operations. Partnerships with laboratories, diagnostic networks, and technology providers remain a core route to expand adoption and reduce implementation friction.
Illumina, Inc. is positioned around a broad sequencing ecosystem that links instruments, consumables, and downstream analysis to support scaled oncology testing workflows. The company’s strategy emphasizes enabling high-throughput clinical operations while supporting assay expansion and improved secondary analysis performance. Continued focus on integrated pipelines and workflow efficiency supports adoption across hospital systems and reference laboratories. This approach aligns with demand for reproducible results, standardized interpretation, and scalable deployment across multi-site testing networks.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In March 2026, Illumina Inc. and Labcorp announced an expanded collaboration to advance precision oncology through next-generation sequencing across the healthcare ecosystem, focusing on developing distributed IVD test offerings, co-commercializing complementary liquid and tissue biopsy assays including the FDA-authorized PGDx elio plasma focus Dx and FDA-approved TruSight Oncology Comprehensive and generating evidence to facilitate payer coverage, with the goal of bringing advanced biomarker testing closer to patients in community health systems and underserved regions.
In May 2025, Illumina Inc. announced an expanded clinical oncology portfolio, unveiling next-generation solutions aimed at advancing precision oncology and improving the standard of care, with the company’s broad range of clinical offerings displayed at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, designed to accelerate access to precision oncology for more patients with cancer.
In February 2025, Roche unveiled its proprietary, breakthrough Sequencing by Expansion (SBX) technology, establishing a novel category of next-generation sequencing; the SBX chemistry, combined with an innovative high-throughput sensor module, offers ultra-rapid sequencing that is both flexible and scalable, with the potential to reduce the time from sample to genome from days to hours, significantly speeding up genomic research and clinical applications in oncology and other complex diseases.
In February 2025, Foundation Medicine launched two new hereditary cancer panels. FoundationOne Germline (50-gene) and FoundationOne Germline More (154-gene) in partnership with Fulgent Genetics, enabling the identification of genetic variants associated with hereditary cancers and enhancing comprehensive genomic profiling capabilities for healthcare providers with germline revenue integrated into tumor–normal paired analyses.
Report Scope
Report Attribute
Details
Market size value in 2025
USD 8206 million
Revenue forecast in 2032
USD 20914 million
Growth rate (CAGR)
14.3% (2025–2032)
Base year
2025
Forecast period
2026-2032
Quantitative units
USD million
Segments covered
By Component Outlook: Instruments / Sequencing Platforms; Kits, Reagents, and Consumables; Software / Bioinformatics Solutions; Services | By Technology Outlook: Targeted Sequencing / Targeted Resequencing; Whole Exome Sequencing (WES); Whole Genome Sequencing (WGS) | By Workflow Outlook: Library Preparation / Pre-Sequencing; Sequencing; Data Analysis / Interpretation | By Application Outlook: Companion Diagnostics; Screening; Tumor Profiling; Liquid Biopsy; Minimal Residual Disease (MRD) Monitoring; Other Applications | By End User Outlook: Hospitals; Clinics; Diagnostic Laboratories; Academic and Research Institutes; Other End Users
Regional scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Market Breakup by Region
11.1. North America
11.1.1. United States
11.1.1.1. Market Trends
11.1.1.2. Market Forecast
11.1.2. Canada
11.1.2.1. Market Trends
11.1.2.2. Market Forecast
11.2. Asia-Pacific
11.2.1. China
11.2.2. Japan
11.2.3. India
11.2.4. South Korea
11.2.5. Australia
11.2.6. Rest of Asia-Pacific
11.3. Europe
11.3.1. Germany
11.3.2. France
11.3.3. United Kingdom
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Latin America
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Middle East and Africa
11.5.1. Market Trends
11.5.2. Market Breakup by Country
11.5.3. Market Forecast
Porter’s Five Forces Analysis
14.1. Overview
14.2. Bargaining Power of Buyers
14.3. Bargaining Power of Suppliers
14.4. Degree of Competition
14.5. Threat of New Entrants
14.6. Threat of Substitutes
Price Analysis
Competitive Landscape
16.1. Market Structure
16.2. Key Players
16.3. Profiles of Key Players
16.3.1. Illumina, Inc.
16.3.1.1. Company Overview
16.3.1.2. Product Portfolio
16.3.1.3. Financials
16.3.1.4. SWOT Analysis
16.3.2. Thermo Fisher Scientific Inc.
16.3.3. F. Hoffmann-La Roche Ltd.
16.3.4. QIAGEN N.V.
16.3.5. Agilent Technologies, Inc.
16.3.6. Pacific Biosciences of California, Inc.
16.3.7. Oxford Nanopore Technologies plc
16.3.8. Bio-Rad Laboratories, Inc.
16.3.9. BGI Group
16.3.10. Revvity, Inc. (formerly PerkinElmer)
16.3.11. Guardant Health
16.3.12. Exact Sciences
Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the market size and forecast for the Clinical Oncology NGS Market?
The market was valued at USD 8206 million in 2025 and is projected to reach USD 20914 million by 2032. Growth reflects expanding clinical adoption of oncology sequencing across care pathways.
What is the CAGR for the Clinical Oncology NGS Market?
The market is expected to grow at a 14.3% CAGR during 2025–2032. This indicates sustained expansion in clinical oncology sequencing utilization.
Which segment is the largest in 2025?
By component, Kits, Reagents, and Consumables is the largest segment with 56.8% share in 2025. Recurring per-test usage supports strong segment leadership.
What factors are driving market growth?
Key drivers include precision oncology expansion, broader CGP utilization, scaling liquid biopsy pathways, and rising monitoring use-cases. Workflow integration and stronger analytics also support adoption across labs and hospitals.
Who are the leading companies in the market?
Leading companies include Illumina, Thermo Fisher Scientific, Roche, QIAGEN, Agilent, Pacific Biosciences, Oxford Nanopore, Bio-Rad, BGI Group, Revvity, Guardant Health, and Exact Sciences. Competition centers on platforms, consumables, assay menus, and interpretation capabilities.
Which region leads the Clinical Oncology NGS Market?
North America leads with 43.6% share in 2025. The region benefits from strong clinical genomics infrastructure and higher precision oncology penetration.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The global Clinical EHR Market size was estimated at USD 42622 million in 2025 and is expected to reach USD 62331 million by 2032, growing at a CAGR of 5.58% from 2025 to 2032.
The global Clear Aligners Market size was estimated at USD 5,136 million in 2025 and is expected to reach USD 8,498 million by 2032, growing at a CAGR of 7.46% from 2025 to 2032.
The global CircRNA Synthesis Market size was estimated at USD 189.75 million in 2025 and is expected to reach USD 527 million by 2032, growing at a CAGR of 15.7% from 2025 to 2032,
The global Circular Dichroism Spectrometers Market size was estimated at USD 38.27 million in 2025 and is expected to reach USD 58 million by 2032, growing at a CAGR of 6.1% from 2025 to 2032.
The global Complex Injectables Market size was estimated at USD 26,141 million in 2025 and is expected to reach USD 46,572 million by 2032, growing at a CAGR of 8.6% from 2025 to 2032.
The global Chronic Venous Occlusions Treatment Market size was estimated at USD 7,419 million in 2025 and is expected to reach USD 9,942 million by 2032, growing at a CAGR of 4.27% from 2025 to 2032.
The global Chronic Kidney Disease Market size was estimated at USD 90,246 million in 2025 and is expected to reach USD 133,030 million by 2032, growing at a CAGR of 5.7% from 2025 to 2032.
The global Carglumic Acid Market size was estimated at USD 126.26 million in 2025 and is expected to reach USD 191 million by 2032, growing at a CAGR of 6.1% from 2025 to 2032.
The global Cardiovascular and Soft Tissue Repair Patches Market size was estimated at USD 5214 million in 2025 and is expected to reach USD 9053 million by 2032, growing at a CAGR of 8.2% from 2025 to 2032.
The global Cheek Augmentation Market size was estimated at USD 4709 million in 2025 and is expected to reach USD 8070 million by 2032, growing at a CAGR of 8% from 2025 to 2032.
The global Cardiovascular Drugs Market size was estimated at USD 157,413 million in 2025 and is expected to reach USD 212,787 million by 2032, growing at a CAGR of 4.4% from 2025 to 2032.
The global Cardiac Sutures Market size was estimated at USD 1,589 million in 2025 and is expected to reach USD 3,019 million by 2032, growing at a CAGR of 9.6% from 2025 to 2032.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
